The DOI matches its Crossref record; 23 of the 27 references it cites were found in a registry or an index.
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak
Open accessAbstract
Abstract The novel COVID-19 outbreak has affected more than 200 countries and territories as of March 2020. Given that patients with cancer are generally more vulnerable to infections, systematic analysis of diverse cohorts of patients with cancer affected by COVID-19 is needed. We performed a multicenter study including 105 patients with cancer and 536 age-matched noncancer patients confirmed with COVID-19. Our results showed COVID-19 patients with cancer had higher risks in all severe outcomes. Patients with hematologic cancer, lung cancer, or with metastatic cancer (stage IV) had the highest frequency of severe events. Patients with nonmetastatic cancer experienced similar frequencies of severe conditions to those observed in patients without cancer. Patients who received surgery had higher risks of having severe events, whereas patients who underwent only radiotherapy did not demonstrate significant differences in severe events when compared with patients without cancer. These findings indicate that patients with cancer appear more vulnerable to SARS-CoV-2 outbreak. Significance: Because this is the first large cohort study on this topic, our report will provide much-needed information that will benefit patients with cancer globally. As such, we believe it is extremely important that our study be disseminated widely to alert clinicians and patients. This article is highlighted in the In This Issue feature, p. 747
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They are among the vulnerable groups because they are at higher risk of being infected and showing more severe symptoms and even death when infected.[13]”
From Psychological Distress of Breast Cancer Survivors During the COVID-19 Pandemic and Related Factors: A Controlled Study. (2023) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Self-citationChen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationCancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
Self-citationPathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30096-6 · Cited by 4,384
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,040
Cited by
Sorted by citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
Terpos, E., Engelhardt, M. M., Cook, G., Gay, F., Mateos, M., Ntanasis‐Stathopoulos, I., van de Donk, N. W. C. J., Avet‐Loiseau, H., Hájek, R., Vangsted, A. J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0876-z · Cited by 736
Determinants of COVID-19 disease severity in patients with cancer
Robilotti, E. V., Babady, N. E., Mead, P. A., Rolling, T., Pérez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M. D., Figueroa, C. J., Glickman, M. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0979-0 · Cited by 634
Lee, L. Y. W., Cazier, J., Starkey, T., Briggs, S., Arnold, R. R., Bisht, V., Booth, S. W., Campton, N. A., Cheng, V. W. T., Collins, G. P., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30442-3 · Cited by 575
Metadata
- Authors
- Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q., Xiong, Y., Xiong, H., Wang, C., Chen, C., Xiong, F., Zhang, Y., Peng, Y., Ge, S., Zhen, B., Yu, T., Wang, L., Wang, H., Liu, Y., Chen, Y., Mei, J., Gao, X., Li, Z., Gan, L., He, C., Li, Z., Shi, Y., Qi, Y., Yang, J., Tenen, D. G., Chai, L., Mucci, L. A., Santillana, M., & Cai, H.
- Affiliations
- Zhongnan Hospital of Wuhan University (CN)
- Boston Children's Hospital (US)
- Brigham and Women's Hospital (US)
- Wuhan Union Hospital (CN)
- Central Hospital of Wuhan (CN)
- Huanggang Central Hospital (CN)
- Guangzhou Medical University (CN)
- Tongji Hospital (CN)
- 16Department of Radiology, Hubei Cancer Hospital, Wuhan, Hubei, China.
- Hubei Cancer Hospital (CN)
- Renmin Hospital of Wuhan University (CN)
- 19Department of Oncology, Wuhan Puren Hospital, Wuhan, Hubei, China.
- Xianning Central Hospital (CN)
- The Central Hospital of Xiao gan (CN)
- 22Department of Obstetrics and Gynecology, The People's Hospital of Huangmei, Huangmei, Hubei, China.
- Hubei University of Medicine (CN)
- Harvard University (US)
- Corresponding author
- Liu, Miao
- Santillana, Mauricio
- Cai, Hongbing
- ORCID
- Venue
- Cancer Discovery
- Published
- 2020-06-01
- Volume
- 10
- Issue
- 6
- Pages
- 783-791
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC7309152
- OpenAlex
- W3015599879
- Cited by
- 1,589
- References
- 27
- Citations by year
- 2026: 16 · 2025: 55 · 2024: 90 · 2023: 218 · 2022: 354 · 2021: 494 · 2020: 356
- FWCI
- 128.41
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer Discovery (publishedVersion)
- SSRN Electronic Journal (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (8197103302/H16)
- Singapore Ministry of Health's National Medical Research Council (MOH-STaR18nov-0002)
- NIH NHLBI (P01HL095489)
- Xiu Research Fund
- Institutional Ethics Board of Zhongnan Hospital of Wuhan University (2020029)
- Topics
- Health Sciences › Medicine › Oncology › COVID-19 and healthcare impacts
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Obstetrics and Gynecology › COVID-19 Impact on Reproduction
- Keywords
- COVID-19 pandemic, SARS-CoV-2, cancer patients, disease severity, hematologic malignancies, lung cancer, metastatic cancer, radiotherapy, infection susceptibility
- MeSH terms
- Betacoronavirus, COVID-19, SARS-CoV-2, Aged, China, Disease Outbreaks, Female, Humans, Intensive Care Units, Male, Middle Aged, Neoplasms, Pneumonia, Viral, Respiration, Artificial, Cohort Studies, Coronavirus Infections, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
